Table 2

 Odds ratios (OR) for a sustained virological response (SVR) with respect to mutation frequency at each of 40 interferon sensitivity determining region (ISDR) sites in Japanese and European patients

ISDRJapan OR (95% CI)Europe OR (95% CI)
*No mutation.
P 220927.46 (13.6–55.5)3.25 (1.6–6.8)
S 22106.0 (0.5–67.3)0.81 (0.7–0.8)
L 221125.21 (3.1–203.2)0.18 (0.1–0.2)
K 22127.29 (3.7–14.5)1.70 (0.5–5.5)
A 22137.71 (1.5–40.1)*
T 221416.8 (8.8–32.0)5.12 (2.4–11.0)
C 221515.25 (4.3–53.8)6.43 (1.1–39.1)
T 221616.87 (8.0–35.8)1.56 (0.7–3.5)
T 22178.78 (4.8–16.1)3.04 (1.4–6.5)
H 22182.50 (1.7–3.6)1.99 (1.2–3.3)
H 22196.46 (3.3–12.7)1.64 (0.6–4.7)
D 22205.20 (3.1–8.8)0.80 (0.7–0.8)
S 222117.98 (6.1–53.2)3.09 (1–9.97)
P 22220.24 (0.2–0.3)0.81 (0.7–0.8)
D 22234.03 (1.5–11.0)2.86 (0.8–10.3)
A 22245.1 (3.3–8.0)9.73 (4.9–19.7)
D 22252.01 (0.3–12.2)4.31 (1.1–17.6)
L 222610.93 (2.2–53.2)0.81 (0.7–0.8)
I 222713.74 (6.8–27.6)3.56 (1.9–6.8)
E 22287.93 (2.5–25.7)8.84 (2.2–36.0)
A 222915.45 (1.8–133.3)0.19 (0.1–0.2)
N 22306.13 (1.1–33.8)*
L 223112.28 (1.4–110.8)0.80 (0.7–0.8)
L 22323.84 (1.0–14.5)0.81 (0.7–0.8)
W 22339.12 (0.9–88.7)17.39 (2.0–157.4)
R 22347.29 (4.1–12.8)1.17 (0.4–3.2)
Q 223510.52 (3.4–32.8)3.44 (0.9–13.1)
E 22369.15 (0.9–88.6)1.64 (0.6–4.7)
M 22372.75 (1.0–7.3)0.80 (0.7–0.8)
G 22386.06 (0.5–67.3)4.24 (0.6–30.5)
G 22390.74 (0.7–0.8)7.29 (2.7–19.3)
N 224018.38 (8.4–40.4)2.71 (1.1–6.7)
I 22411.50 (0.1–16.7)2.55 (0.6–10.9)
T 22420.75 (0.7–0.8)0.80 (0.7–0.8)
R 2243*0.80 (0.7–0.8)
V 2244*8.68 (1.6–48.1)
E 22450.75 (0.7–0.8)17.39 (1.9–157.4)
S 22460.75 (0.7–0.8)*
E 22470.25 (0.2–0.3)10.43 (2.7–41.1)
N 224811.29 (4.1–31.1)2.86 (0.8–10.3)